XOMA Royalty (STU:X0M1) Debt-to-Equity : 1.46 (As of Dec. 2024)

View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Debt-to-Equity?

XOMA Royalty's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €11.31 Mil. XOMA Royalty's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €102.53 Mil. XOMA Royalty's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €78.24 Mil. XOMA Royalty's debt to equity for the quarter that ended in Dec. 2024 was 1.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for XOMA Royalty's Debt-to-Equity or its related term are showing as below:

STU:X0M1' s Debt-to-Equity Range Over the Past 10 Years
Min: -21.08 Med: 0.75 Max: 2.52
Current: 1.46

During the past 13 years, the highest Debt-to-Equity Ratio of XOMA Royalty was 2.52. The lowest was -21.08. And the median was 0.75.

STU:X0M1's Debt-to-Equity is ranked worse than
92.12% of 1015 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:X0M1: 1.46

XOMA Royalty Debt-to-Equity Historical Data

The historical data trend for XOMA Royalty's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Debt-to-Equity Chart

XOMA Royalty Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.25

1.40

1.46

XOMA Royalty Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															1.40	1.47	1.22	1.40	1.46

Competitive Comparison of XOMA Royalty's Debt-to-Equity

For the Biotechnology subindustry, XOMA Royalty's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XOMA Royalty's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

XOMA Royalty Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

XOMA Royalty's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.307	+	102.527)	/	78.235
	=	1.46

XOMA Royalty's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.307	+	102.527)	/	78.235
	=	1.46

XOMA Royalty (STU:X0M1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

XOMA Royalty Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (STU:X0M1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA 0M26:UK

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines